Inventor · disambiguated record
Sebastian Kreiter
Also filed as: KREITER SEBASTIAN
23 granted patents·15 pending applications·193 citations·filing 2004–2024
95Inventor score
Top patents by PatentIndex Score
38 records- 0196US10106800B2Modification of RNA, producing an increased transcript stability and translation efficiencyBIONTECH AG·Filed 2016·Granted Oct 23, 2018·18 cites·11 claims
- 0294US10738355B2Individualized vaccines for cancerSAHIN UGUR·Filed 2012·Granted Aug 11, 2020·41 cites·25 claims
- 0394US9476055B2Modification of RNA, producing an increased transcript stability and translation efficiencySAHIN UGUR·Filed 2006·Granted Oct 25, 2016·29 cites·19 claims
- 0491US11248264B2Individualized vaccines for cancerTRON TRANSLATIONALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ GGMBH·Filed 2020·Granted Feb 15, 2022·5 cites·19 claims
- 0591US10576146B2Particles comprising a shell with RNABIONTECH RNA PHARMACEUTICALS GMBH·Filed 2018·Granted Mar 3, 2020·13 cites·15 claims
- 0689US11559587B2RNA formulation for immunotherapyBioNTech SE·Filed 2019·Granted Jan 24, 2023·3 cites·44 claims
- 0789US10485884B2RNA formulation for immunotherapyBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2013·Granted Nov 26, 2019·16 cites·39 claims
- 0887US11045418B2Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cellBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2016·Granted Jun 29, 2021·3 cites·8 claims
- 0987US10669322B2RNA molecules encoding cytokine fusion proteins and methods of use thereofBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2016·Granted Jun 2, 2020·4 cites·28 claims
- 1087US9950065B2Particles comprising a shell with RNABIONTECH AG·Filed 2013·Granted Apr 24, 2018·12 cites·20 claims
- 1187US9486519B2Use of FLT3 ligand for enhancing immune responses in RNA immunizationSAHIN UGUR·Filed 2009·Granted Nov 8, 2016·15 cites·6 claims
- 1287US8178653B2Recombinant vaccines and use thereofTUERECI OEZLEM·Filed 2004·Granted May 15, 2012·20 cites·4 claims
- 1385US8637006B2Recombinant vaccines and use thereofTUERECI OEZLEM·Filed 2012·Granted Jan 28, 2014·6 cites·10 claims
- 1483US12385049B2Modification of RNA, producing an increased transcript stability and translation efficiencyBioNTech SE·Filed 2022·Granted Aug 12, 2025·0 cites·30 claims
- 1582US11156617B2Predicting T cell epitopes useful for vaccinationBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2016·Granted Oct 26, 2021·3 cites·21 claims
- 1679US10301368B2Cytokine fusion proteinsBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2016·Granted May 28, 2019·4 cites·22 claims
- 1777US11318195B2Formulation for administration of RNABIONTECH RNA PHARMACEUTICALS GMBH·Filed 2017·Granted May 3, 2022·1 cites·39 claims
- 1877US2022257783A1Recombinant vaccines and use thereofBioNTech SE·Filed 2022·Application pending·0 cites
- 1973US11337922B2Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cellBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2021·Granted May 24, 2022·0 cites·17 claims
- 2073US2022282322A1Individualized vaccines for cancerTRON TRANSLATIONALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ GG·Filed 2022·Application pending·0 cites
- 2172US2023226217A1Rna formulation for immunotherapyTRON TRANSLATIONALE ONKOLOGIE AN DER UNIV DER JOHANNES GUTENBERG UNIV MAINZ AD·Filed 2022·Application pending·0 cites
- 2271US2025213599A1Formulation for administration of rnaBioNTech SE·Filed 2024·Application pending·0 cites
- 2370US2022249372A1Lipid Particle Formulations for Delivery of RNA and Water-Soluble Therapeutically Effective Compounds to a Target CellBioNTech SE·Filed 2022·Application pending·0 cites
- 2468US2023330198A1Rna for treatment of autoimmune diseasesBioNTech SE·Filed 2023·Application pending·0 cites
- 2567US2019062762A1Modification of RNA, Producing an Increased Transcript Stability and Translation EfficiencyBIONTECH AG·Filed 2018·Application pending·0 cites
- 2666US11298426B2Recombinant vaccines and use thereofBioNTech SE·Filed 2018·Granted Apr 12, 2022·0 cites·21 claims
- 2765US11660338B2Particles comprising a shell with RNABioNTech SE·Filed 2020·Granted May 30, 2023·0 cites·27 claims
- 2863US12150947B2Formulation for administration of RNABioNTech SE·Filed 2019·Granted Nov 26, 2024·0 cites·16 claims
- 2963US2022313811A1Formulation for administration of rnaBioNTech SE·Filed 2022·Application pending·0 cites
- 3062US2014134201A1Recombinant vaccines and use thereofBIONTECH AG·Filed 2014·Application pending·0 cites
- 3160US2025295744A1Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonistsBioNTech SE·Filed 2022·Application pending·0 cites
- 3260US2022074948A1Predicting t cell epitopes useful for vaccinationBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2021·Application pending·0 cites
- 3357US11701413B2RNA for treatment of autoimmune diseasesBioNTech SE·Filed 2018·Granted Jul 18, 2023·0 cites·8 claims
- 3454US2023145774A1Treatment involving non-immunogenic rna for antigen vaccinationBioNTech SE·Filed 2021·Application pending·0 cites
- 3552US10808019B2Nucleic acid molecules encoding cytokine fusion proteins comprising tumor necrosis factor (TNF) superfamily ligandsBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2019·Granted Oct 20, 2020·0 cites·21 claims
- 3650US2022378876A1Treatment Involving Therapeutic Antibody and Interleukin-2 (IL2)BioNTech SE·Filed 2020·Application pending·0 cites
- 3747US2022143144A1Treatment involving interleukin-2 (il2) and interferon (ifn)BioNTech SE·Filed 2020·Application pending·0 cites
- 3845US2021113606A1Treatment using cytokine encoding rnaBIONTECH RNA PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →